NEW YORK, Feb 15 – Variagenics said Thursday its fourth-quarter revenues jumped to $1.2 million, compared with $100,000 in the previous year while revenues for the year rose to $2.3 million from $400,000.

"The year 2000 was pivotal for Variagenics as we commercialized our proprietary technologies for identifying drug-specific genetic markers," Taylor Crouch, CEO of Variagenics, said in a statement. "We are pursuing a vision to place Variagenics' pharmacogenomics at the heart of a new generation of individualized drugs and companion diagnostics.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.